
Separately, AstraZeneca has appointed OgilvyHealth to develop and manage disease awareness and educational programmes for six products in Indonesia, Crestor (a cholesterol treatment), Nexium (a gastric acid drug), Symbicort (an asthma medication), Seroquel (a mood stabiliser), Iressa (a lung cancer treatment), and Arimidex (a post-menopausal hormonal balancing drug).
Meanwhile in Australia, the Lance Armstrong Foundation is to work with OgilvyHealth to generate media interest in its launch in Australia and draw attention to key areas of need in cancer treatment. The appointment, which was also non-competitive, coincides with Tour de France hero and former cancer patient Armstrong’s return to competitive cycling.
Chris Graves, president and chief executive of Ogilvy Public Relations in Asia-Pacific, said that the agency would be focusing on its developing high-end research and medical education capabilities going forward. He added that the healthcare sector represented significant opportunities for growth in Asia, describing chronic disease, particularly cancer, as “a big wave” closing in on the region as a result of changing lifestyles.